NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.11 -2.82 (-3.44%) GOLD FUTURES
2,327.70 +24.80 (+1.08%) DOW
37,908.37 +92.45 (+0.24%) Bitcoin GBP
45,722.96 -1,761.45 (-3.71%)
BiomX Inc. (PHGE)
| Previous close | 0.4790 |
| Open | 0.4500 |
| Bid | 0.4516 x 1300 |
| Ask | 0.4530 x 2900 |
| Day's range | 0.3900 - 0.4599 |
| 52-week range | 0.1870 - 0.8550 |
| Volume | |
| Avg. volume | 2,714,426 |
| Market cap | 24.849M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of
- GlobeNewswire
BiomX Announces the Appointment of Susan Blum to its Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. “We are pleased to welcome Susan Blum to our Board of Directors who join
- GlobeNewswire
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualificati
